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930Impact of Bone Marrow Hematogones on Umbilical
Cord Blood Transplantation Outcomes in Patients
with Acute Myeloid Leukemia
Theodore Honebrink,1 Vanessa Dayton,1 Michael J. Burke,5 Karen Larsen,2 Qing Cao,3
Claudio Brunstein,4 Daniel Weisdorf,4 Jeffery S. Miller,4 John E.Wagner,5 Michael R. Verneris5Early after umbilical cord blood transplantation, patients showmarked differences in bonemarrow (BM) hem-
atogone percentages. Little is known about whether these differences are clinically relevant.We hypothesized
that early recovery of hematogones may be associated with improved transplantation outcomes. BM aspirates
were assessed from 88 patients with acute myeloid leukemia by two independent reviewers at day 21 and 100
after umbilical cord blood transplantation. Interobserver variability for BM hematogone percentages at these
time points showed correlation coefficients of 0.83 and 0.98, respectively (P#.01 for both). A high percentage
of hematogones at day 21was associatedwith less acute graft-versus-host disease grade 3 to 4 (P5.01). At day
100, a high percentage of BM hematogones was associated with improved overall survival (P5 .02) and lower
treatment-related mortality (P#.01). This study shows that BM hematogone percentages may be useful prog-
nostic indicators in patients with acutemyeloid leukemia after umbilical cord blood transplantation and should
be routinely reported in BM differential counts.
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Hematogones were first described in the 1930s
as lymphoid-appearing cells present in the sternal
aspirates of children undergoing evaluation for an
assortment of neoplastic, congenital, infectious, and
autoimmune diseases [1,2]. Although their biologic
significance was unclear, authors speculated on
their role in hematopoiesis, with some considering
hematogones to be undifferentiated primordial cells
(hemocytoblasts) [1-3]. Eventually, the name
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6/j.bbmt.2011.11.015Latin), was adopted [1,2]. Since that time, numerous
studies document that they represent B-lymphocyte
precursors that reside in the marrow and that undergo
an orderly maturation sequence to give rise to mature
B cells [4-10]. By flow cytometry, hematogones have
been characterized into several stages using CD10,
CD19, CD20, CD22, CD34 and CD38 [9]. Although
this method is very effective in characterizing the mat-
urational spectrum of hematogones, the wide variation
in flow cytometry protocols limits the determination of
cell percentages; therefore, assessment by morphology
is standard for all current classification systems [11].
Hematogones may be increased in numerous neo-
plastic as well as nonneoplastic conditions including
marrow regeneration and immune deficiencies
[4,6-10,12-21]. One situation where increased
percentages of hematogones are commonly observed
is in the post-umbilical cord blood transplantation
(UCBT) setting [17,22,23]. UCBT has been shown
to have high numbers and increased generative
capacity of B-lymphocyte progenitors [24]. For un-
known reasons, elevated hematogone percentages are
noted in some but not other UCBT patients. Whether
there is a prognostic association between the presence
of bone marrow (BM) hematogones and clinical out-
comes in UCBT is unknown. This lack of information
may explain why hematogones are not routinely re-
ported in BM differential counts and are, instead, com-
bined with other lymphocytes.
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morphologic detection of hematogones in the BM of
transplantation recipients or whether hematogone per-
centages are associated with posttransplantation out-
comes. Considering that hematogones give rise to
B cells that provide protection against pathogens and
that in nontransplantation patients, the percentage of
hematogones in the BM is inversely correlated with
the percentage of leukemic blasts in the marrow [9,25],
we hypothesized that increased hematogones would be
associated with superior transplantation outcomes.
To address this hypothesis, we assessed the per-
centage of BM hematogones in a cohort of 91 consecu-
tive patients with acute myelogenous leukemia (AML)
treatedwith allogeneic single or doubleUCBT.Recog-
nizing that any associations between hematogones and
clinical outcomes are only useful if they can be repro-
ducibly recognized, we also determined the correlation
between two independent observers in the assessment
of the percentage hematogones in themarrow aspirates
at day 21 and day 100 after transplantation.METHODS
Patients
Ninety-one consecutive patients with AML under-
going myeloablative UCB transplantation were stud-
ied. We included patients who had undergone UCB
transplantation at the University of Minnesota be-
tween February 1999 and July 2008. Patients were
required to have a BM biopsy with no evidence of
relapse at the time of the marrow analysis. Hemato-
gone determinations were performed on day 21 and
100 post-UCB transplantation (ie, day 21 or 100)
samples. Patients who relapsed between day 21 and
day 100 were censored for the day- 100 hematogone
determination. Because of the morphologic similarity
between hematogones and leukemic lymphoblasts,
only patients with AML were included in this analysis.
Of 91 eligible patients with AML receiving UCBT
during the study period, three were excluded due to
early posttransplantation relapse (n 5 2) or lack of
availability of any interpretable slides for review (n 5
1). A summary of exclusion criteria is provided in
Supplemental Table 1, online only. Of the 88 remain-
ing patients, 85 had interpretable slides available for
review at day 21. Sixty-six cases were available for
review at both day 21 and day 100, whereas 19 cases
were reviewed at only day 21, and three cases were re-
viewed only at day 100. Overall, 154 cases from 88 pa-
tients (88 of 91) fit the above criteria and had material
adequate for differential counts.
Morphologic Analysis
Wright-Giemsa stained direct and concentrate
BM aspirate smears and trephine touch imprintpreparations were each reviewed independently by
a faculty hematopathologist (V.J.D.) and pathology
resident (T.J.H.). The specimens used to perform
differential counts were, in order of preference, direct
smears, touch preparations, and concentrate smears.
In general, touch preparations were used in cases in
which aspirates were hemodilute or not available. Con-
centrate smears were used in cases with hypocellular
aspirates. Before the beginning of the study, both
reviewers concurrently examined several cases noted
to have high percentages of hematogones and came to
agreement on morphologic features useful in distin-
guishing hematogones from mature lymphocytes. A
500- cell differential count, including hematogones,
was performed in each case, except in instances where
low cellularity precluded a full 500-cell count. In those
cases, a 50- to 300-cell differential count was per-
formed. A 50-cell differential count was performed in
one case only, on a concentrate smear. Hematogones
had condensed and homogenous nuclear chromatin
without significant clumping, high nuclear- to- cyto-
plasmic (N/C) ratios with a thin rim of eccentric baso-
philic cytoplasm, and no cytoplasmic vacuoles,
inclusions, or granules. When present, nucleoli were
indistinct. In contrast, mature lymphocytes had coarse,
clumped chromatin, lower N/C ratios and more abun-
dant cytoplasm with variable cytoplasmic inclusions
and granules (Figure 1).
Interobserver Variability in the Morphological
Assignment of Hematogones
In 146 of 154 cases (94.8%), the hematogone per-
centages reported by the two observers were within
3.6%. The remaining eight cases (5.2%) were jointly
reviewed, and a consensus was reached after which
interobserver variability for percent hematogones
reported at days 21 and 100 was calculated using
Pearson correlation. Correlation coefficients at days
21 and 100 were 0.83 and 0.98, respectively (P # .01
for both) [26]. For the analysis (to follow) correlating
hematogone percentagewith transplantation outcomes,
the average percentage from the two reviewerswas used.
Flow Cytometric Immunophenotyping
The clinical laboratory database for all patients
with slides available for microscopic review was
searched in order to determine whether flow cytomet-
ric immunophenotyping was performed on the mar-
row aspirate and whether a percentage value for
hematogones was reported at the time of the original
study. Flow cytometry was performed on BM aspirates
that were collected in sodium heparin. After lysis of
erythrocytes (ammonium chloride), the cells were
washed twice with phosphate-buffered saline and
stained according to the manufacturers’ recommenda-
tions with a panel of monoclonal antibodies directly
Figure 1. Morphologic appearance of hematogones (A) and lymphocytes (B). (A), Hematogones had condensed and homogenous nuclear chromatin
without significant clumping, high nuclear- to- cytoplasmic (N/C) ratios with a thin rim of eccentric basophilic cytoplasm, no cytoplasmic vacuoles,
inclusions or granules, and no distinct nucleoli (open arrow). (B), In contrast to the hematogones pictured opposite, lymphocytes had coarse, clumped
chromatin and more abundant cytoplasm (closed arrow).
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Jose, CA). Data were acquired on a FACSCaliber
(B.D. Biosciences) using CELL Quest Pro and
analyzed using FACS Diva software.
Assessment of Patient Absolute Lymphocyte
Count
The medical records were reviewed for patients,
and absolute lymphocyte counts (ALCs) were obtained
as previously described [27]. Briefly, ALCs were col-
lected from the medical records at day 30 (13 days).
ALCs were recorded as missing if the WBC was
\0.5  109/L, as no manual differential counts were
performed during severe leukopenia. Correlation be-
tween average percentage hematogone and ALC was
performed using X2 analysis.
Statistical Analysis
Data on transplantation patient characteristics,
posttransplantation complications and outcomes
were prospectively collected by the Biostatistical
Support Group at the University of Minnesota using
standardized collection procedures. Details regarding
graft selection, conditioning regimens, and graft-
versus-host disease (GVHD) prophylaxis have been
previously described [28-30]. Patients and disease
characteristics were summarized using descriptive
statistics. Statistical comparisons of these variables
between high and low hematogone percentage were
completed by a nonparametric Wilcoxon test for
continuous factors and Pearson X2 test for
categorical factors. All patients were followed
longitudinally until death or last follow-up. The end-
points included neutrophil and platelet recovery,
overall survival (OS), disease-free survival (DFS),
transplantation-related-mortality (TRM), risk of re-
lapse, acute GVHD (aGVHD), and chronic GVHD
(cGVHD). Kaplan-Meier [31] was used to estimate
neutrophil recovery, OS, and DFS. Cumulative inci-
dence [32] was used to estimate platelet recovery, re-
lapse, TRM, aGVHD, and cGVHD. Statisticalcomparison of neutrophil, OS, and DFS between
groups was completed by the log-rank test. The pro-
portional hazards model of Fine and Gray [33] was
used to assess the independent factors on platelet re-
covery, relapse, TRM, aGVHD, and cGVHD. Factors
included in multivariate analysis were hematogone
percentage (low vs high), donor number (single vs dou-
ble), recipient age (\21 vs$21), recipient cytomegalo-
virus (CMV) status (negative vs positive), total,
postthaw CD34 (\0.50 vs$0.50), total, postthaw col-
ony-forming unit (\0.042 vs$0.042), and total nucle-
ated cell (\0.38 vs $0.38). The backward stepwise
method was used to decide the final model. Groups
with a P value of #.05 were considered to be statisti-
cally different.RESULTS
Percentage Marrow Hematogones and
Transplantation Outcomes
Patients were grouped into quartiles based on the
average percentage of BM hematogones (determined
using morphology by two reviewers) at day 21 and
day 100 after transplantation. In univariate analysis,
those in the lowest quartile had differing outcomes
compared to patients in the upper three quartiles
(not shown). Based on these findings, patients were
grouped using the 25th percentile (0% at 21 days after
UCBT and 0.9% at 100 days after UCBT) as a cutoff.
There were no demographic differences between
patients who had a low or high percentage of hemato-
gones at day 21 (Supplemental Table 2, online only) or
day 100 (Table 1).
At day 121 after transplantation, the percentage
of marrow hematogones varied from 0% to 10.8%
(n 5 91). In assessing these percentages, we observed
that patients in the lowest quartile (corresponding to
those with hematogones 5 0%) were more likely to
develop grade III to IV aGVHD (38%, 95%
confidence interval [CI], 20%-57% vs 22%; 95%
CI, 11%-32%; P 5 .05). This association was
Table 1. Patient Demographics Based on Percentage of Hematogones in the Marrow at Day 100 after UCBT
Factor Number (%)
Hematogones at Day 100 Number (%)
P value5 0.9 > 0.9
Number of UCB units .20
Single 21 (32) 3 (5) 18 (27)
Double 45 (68) 13 (20) 32 (48)
Gender .55
Male 37 (56) 10 (15) 27 (41)
CMV status .53
Positive 41 (62) 11 (17) 30 (45)
HLA (engrafting unit) .96
4/6 29 (44) 7 (11) 22 (33)
5/6 28 (42) 6 (10) 22 (33)
6/6 8 (12) 2 (3) 6 (10)
Disease status .60
CR1 27 (41) 8 (12) 19 (29)
CR2 36 (54) 7 (11) 29 (44)
CR3 3 (5) 1 (2) 2 (3)
Conditioning
MA 66 (100) 16 (24) 50 (76) –
Total nucleated dose (x107/kg) 0.41 (0.14-2.80) 0.42 (0.23-1.47) 0.40 (0.14-2.80) .64
CD3 cell dose/kg (x106/kg) 0.14 (0.04-0.56) 0.13 (0.04-0.51) 0.15 (0.04-0.56) .82
CD34 cell dose/kg (x106/kg) 0.50 (0.13-27.53) 0.46 (0.14-1.59) 0.50 (0.13-27.53) .54
Recipient age 21 (0-44) 22 (2-44) 21 (0-44) .66
UCBT indicates umbilical cord blood transplantation; UCB, umbilical cord blood; CMV, cytomegalovirus; HLA, human leukocyte antigen values corre-
spond to number of matched allelic loci for HLA-A, HLA-B, and HLA-DR between recipient and engrafting donor; MA, myeloablative; CD34, CD34 cell
dose of transplanted cord blood unit(s).
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with hematogones in the lowest quartile were
more likely to develop severe aGVHD (P 5 .01)
(Table 2). Based on multivariate analysis, hemato-
gone percentages at day 21 were not associated
with OS, DFS, TRM, neutrophil engraftment, plate-
let engraftment, or cGVHD (Table 2). In multivari-
ate analysis, patients in the upper three quartiles
(with hematogone percentages .0) had a relative
risk of relapse of 8.48 (95% CI, 0.82-88.06) compared
to those with hematogones 5 0 (P 5 .07) (Table 2).
Patients who had a high BM hematogone percentage
at day 21 tended to have a high percentage at day
100 as well. More specifically, of the 66 patients who
had hematogone analysis at both day 21 and day
100, 47 patients at day 21 had a hematogone percent-
age of .0. Forty of these patients (85%) remained in
the high hematogone group at day 100 (P 5 .01).
At day1100 after transplantation, the percentage of
hematogones varied from 0% to 29.6% (n5 66). At this
time, the percentage of hematogones wasmore strongly
associated with transplantation outcomes. In univariate
analysis, patients with high hematogone percentages (ie,
upper three quartiles [. 5 0.9%]) had a 3-year OS of
76% (95% CI, 61%-85%) compared to 49% (95%
CI, 61%-85%) for those with hematogone percentages
in the lowest quartile (\0.9%; P5 .02) (Figure 2A). As
shown in Table 3, this was confirmed in multivariate
analysis, where patients with a high percentage of hem-
atogones in the marrow were five-fold more likely to
survive (relative risk [RR], 0.20; 95% CI, 0.05-0.76;
P5 .02). This improvement in OS was due to a reduc-
tion inTRM. In univariate analysis, patients with a highhematogone percentage ($0.9%) at day 100 showed
a 1-year TRM rate of 2% (95%CI, 0%-6%) compared
to 31% (95% CI, 9%-54%; P\ .01) (Figure 2B). This
was again confirmed in multivariate analysis (Table 3),
where increased hematogone percentages ($0.9%) at
day 100 were associated with a relative risk of TRM of
0.03 (95% CI, 0-0.34; P # .01). Hematogone percent-
ages at day 100 were not associated with DFS, relapse,
neutrophil engraftment, platelet engraftment, or
cGVHD on multivariate analysis (Table 3).Morphologic Correlation with FACS
Assessment of Hematogones
Review of the laboratory database showed that
prior to 2007, flow cytometric immunophenotyping
was rarely performed on BM aspirates of post-
UCBT patients with AML at our center. Flow cyto-
metric immunophenotyping included a percentage
hematogones in the final report for 11 of the flow
cytometry cases. As shown in Figure 3, hematogone
determination by flow cytometry was correlated with
that determined by morphology (P 5 .05) in the
limited cases where data were available.
Marrow Hematogone Percentage is not
Associated with Absolute Lymphocyte Count
We have recently determined that rapid lympho-
cyte recovery after UCBT is associated with improved
transplantation outcomes [27]. In that study, patients
treated with myeloablative transplantation showed
superior outcomes (OS, PFS, and TRM) if their
ALC was.200 106/L at day130. We hypothesized
Table 2. Multivariate Analysis Examining the Percentage of
Hematogones Detected in the BM at Day 21 after UCBT
Outcome Variable RR (95% CI) P value
DFS Donor number .04
1 1
2 0.13 (0.02-0.90)
Relapse Hem at day 21
50 1.00
>0 8.48 (0.82-88.06) .07
Donor number
1 1.00
2 0.33 (0.12-0.95) .04
ANC Hem at day 21
50 1.00
>0 0.95 (0.43-2.09) .89
CD34
<0.50 1.00
$0.50 3.70 (1.29-10.62) .01
TRM Hem at day 21
50 1.00
>0 0.45 (0.15-1.33) .15
aGVHD III-IV Hem at day 21
50 1.00
>0 0.30 (0.15-0.59) .01
Donor number
1 1.00
2 5.44 (1.41-20.92) .01
Receiver CMV
Negative 1.00
Positive 5.97 (2.03-17.58) <.01
CFU
<0.0419 1.00
$0.0419 0.28 (0.10-0.74) .01
cGVHD Hem at day 21
50 1.00
>0 1.90 (0.47-7.74) .37
BM indicates bone marrow; UCBT, umbilical cord blood transplantation;
RR, relative risk; CI, confidence interval; DFS, disease-free survival;
Hem, percentage of hematogones; ANC, absolute neutrophil count;
CD34, CD34 cell dose of transplanted cord blood unit(s); TRM,
transplantation-related mortality; aGVHD III-IV, acute graft-versus-
host disease, grade 3-4; CMV, cytomegalovirus; CFU, colony- forming
units; cGVHD, chronic graft-versus-host disease.
Figure 2. Bone marrow (BM) hematogones at day 100 are associated
with transplantation outcomes. (A), Probability of 1-year overall survival
(OS) based on the percentage of hematogones in the BM at day 100 after
transplantation. (B), Cumulative incidence of treatment-related mortal-
ity (TRM) based on the percentage of hematogones in the BM at day 100
after transplantation.
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be correlated at day 21 and/or day 100. As shown in
Table 4, ALC at day 30 was available in the medical
records for 61 patients at day 21 and 56 patients at
day 100. Surprisingly, there was no correlation be-
tween ALC and hematogone percentage in the mar-
row at either day 21 or day 100. Thus, hematogone
percentage is independent of ALC (P 5 .86 and .12,
respectively), but both are associated with UCBT out-
comes (above and [27]).DISCUSSION
We investigated whether the percentage of mar-
row hematogones as determined by morphology was
associated with UCBT outcomes in a population of
uniformly treated adults and children with AML.
Our results show that increased percentages of hema-
togones in the BM at day 21 were associated with lower
rates of grade III to IV aGVHD, likely suggesting that
severe aGVHD interferes with B cell reconstitution.At day 100, high percentages of hematogones were
associated with improved 3-year OS, due to lower
1-year TRM. Although recent studies show a relation-
ship between the presence of hematogones detected by
flow cytometry and improved OS in patients with
AML receiving chemotherapy, multivariate analysis
could not confirm those findings [34]. Our study dem-
onstrates that increased numbers of hematogones are
an independent predictor of OS and TRM in a subset
of patients with AML undergoing UCBT. We specif-
ically chose patients with AML for this study due to the
concern for morphologic similarity between hemato-
gones and lymphoblasts. Thus, additional studies are
needed to investigate whether increased marrow hem-
atogones are associated with similar outcomes in other
diseases, including acute lymphoblastic leukemia or
lymphoma.
In this study, only a limited number of cases were
reviewed by flow cytometry considering that BM
flow cytometry for AML was not the standard of care
at the time of the study. However, of the limited cases,
there was adequate correlation between morphology
and flow cytometry. Based on this, and because the rel-
ative quantification of marrow constituents using flow
cytometry is problematic, we chose to assess hemato-
gones using morphology in this study. Current
Table 3. Multivariate Analysis Examining the Percentage
Hematogones Detected in the BM at day 100 after UCBT
Outcome Variable RR (95% CI) P value
Overall survival Hem at day 100
<0.9 1.00
$0.9 0.20 (0.05-0.76) .02
Donor number
1 1.00
2 0.19 (0.04-0.84) .03
Transplantation age
<20.5 1.00
$20.5 4.89 (1.11-21.51) .04
Relapse Hem at day 100
<0.9 1.00
$0.9 2.84 (0.32-24.91) .35
TRM Hem at day 100
<0.9 1.00
$0.9 0.03 (0-0.34) <.01
HLA (engrafting unit)
4/6 1.00
5/6 0.61 (0.05-7.13) .69
6/6 0 <.01
cGVHD Hem at day 100
<0.9 1.00
$0.9 0.44 (0.11-1.69) .23
Transplantation age
<20.5 1.00
$20.5 3.61 (1.18-11.06) .02
BM indicates bonemarrow; UCBT, umbilical cord blood transplantation;
RR, relative risk; CI, confidence interval; Hem, percentage of hemato-
gones; TRM, transplantation-related mortality; HLA, human leukocyte
antigen, values correspond to number of matched allelic loci for HLA-
A, HLA-B, and HLA-DR between recipient and engrafting donor;
cGVHD, chronic graft-versus-host disease.
Table 4. Association of Day 21 and Day 100 Hematogone
Count with ALC
Hem Day 21 5 0 Hem Day 21 >0 P value
ALC D30 <200 5 (27%) 13 (72%) .86
ALC D30 $200 11 (26%) 32 (74%)
Hem Day 100 5 0.9 Hem Day 100 $0.9 P value
ALC D30 <200 5 (33%) 10 (67%) .12
ALC D30 $200 6 (15%) 35 (85%)
D30 indicates day 30; ALC, absolute lymphocyte count; Hem, percent-
age of hematogone.
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cell types, such as erythroid precursors, are lost when
a lysis step is incorporated. This would artificially in-
crease hematogone percentages. Likewise, various gat-
ing strategies may include cells that do not represent
hematogones, or alternatively may exclude true hema-
togones. This would artificially increase or decrease
the calculated hematogone percentage, respectively.Spearman Coefficient = 0.61
P = .05
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Figure 3. Correlation of bone marrow hematogones with flow cytom-
etry. Shown is the correlation for the 11 cases that had both morpho-
logic determination of hematogone percentage by morphology and
flow cytometry where percentage of hematogones were reported.In addition, samples submitted for flow cytometry
often represent the second aspirated specimen and
are hemodilute, artificially lowering hematogone
percentages. Thus, we chose to perform morphologic
assessment as the ‘‘gold standard’’ for quantification of
marrow hematogones. As flow cytometry becomes
more standardized across institutions, future studies
should be performed to determine whether this modal-
ity is also associated with transplantation outcomes.
While we provide evidence that marrow hemato-
gones are associated with UCBT outcomes, there are
limitations to this study. First, this is a single- institu-
tion study, which may introduce not only patient bias,
but also subjectivity in the assessed morphologic
parameters. Another potential limitation relates to
specimen preparation. All direct smears were prepared
at the bedside during the marrow aspirate procedure
by hematology technicians and were stained by hand.
This method, in our experience, facilitates a more
accurate assessment of the BM cellular composition.
In contrast, anticoagulated specimens processed by
automated machine stainers may preclude accurate
assessment of the cellular constituents, limiting the
applicability of these findings.
One of the largest causes of mortality in patients
undergoing UCBT is infections, predominantly
during the lymphopenic period [35]. Although we
demonstrate that increased percentages of marrow
hematogones correlate well with clinical outcomes, it
is not clear that their increase predicts immunity or
that immunity from infection is the explanation for
improved outcomes. In fact, in a subset of patients,
there was no correlation of BM hematogone percent-
ages with serum immunoglobulin levels at 100 or
365 days after transplantation (not shown). Likewise,
detailed B cell immunological reconstitution was not
routinely performed on this cohort; therefore, how
these data are related to mature B cell recovery will
be the subject of additional studies.
In summary, patients with AML undergoing
UCBT with increased BM hematogones have less
aGVHD, less TRM, and improved OS. Additional
prospective studies are needed in other diseases
because these results could become a useful tool to
predict posttransplantation outcomes.
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